IMP3

Across TCGA pan-cancer cohorts, IMP3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IMP3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where IMP3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types IMP3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where IMP3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IMP3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.508	<.001	12	view →
COAD	Male	All	+0.592	<.001	11	view →
LSCC	All	II,III,IV	+0.641	<.001	8	view →
HNSC	Male	IV	+0.419	<.001	8	view →
LUAD	Male	II,III,IV	+0.263	<.001	8	view →
PDAC	Female	II,III,IV	−0.496	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IMP3–CCRCC

Open the CCRCC breakdown →